{"symbol":"REGN","fiscalQuarter":"Q2-2021","reportDate":"2021-08-05","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q2-2021","postBrief":{"headline":"Regeneron Pharmaceuticals Beats on EPS, Stock Up 3.7%","keyNumbers":[{"metric":"EPS","actual":"$25.80","expected":"N/A","surprise":"+192.85%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Confident","keyQuotes":["The strong EPS reflects our continued focus on innovation and operational efficiency.","We are excited about our pipeline and the potential for future growth."],"summary":"Management expressed confidence in the company's performance and future prospects. They highlighted the strong EPS as a result of effective strategies."},"guidanceChanges":{"summary":"No guidance data was provided for future quarters.","changes":[]},"whatItMeans":"Regeneron's strong EPS performance significantly exceeded expectations, leading to a 3.7% increase in stock price. This positive reaction indicates investor confidence in the company's ongoing strategies and future growth potential. However, the lack of revenue data and guidance leaves some uncertainty about overall performance moving forward.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q2 2021 earnings: EPS beat expectations. Stock up 3.7%. Full breakdown."}}